Market Performance - The U.S. stock market opened mixed with the Dow Jones up by 0.38%, while the Nasdaq and S&P 500 indices were down by 0.24% and 0.04% respectively. As of the report, the Dow Jones was up by 0.27%, the Nasdaq down by 0.84%, and the S&P 500 down by 0.36% [2] - A total of 2,712 stocks rose while 2,381 stocks fell [2] Company Specifics - Nvidia's earnings report exceeded expectations but received a lukewarm response, leading to a stock price drop of over 3.6% [2] - Major Chinese concept stocks mostly declined, with BeiGene down by 6.56%, Beike down by 5.85%, Baidu down by 4.83%, and Luckin Coffee down by 4.71% [3][4] - Baidu reported a year-over-year revenue decrease of 3% for the fiscal year 2025 [3] Commodity Market - International silver prices continued to decline, with COMEX silver futures dropping over 5% and spot silver down by over 3%. As of the report, COMEX silver futures were down by 4.6% and spot silver by 2.55% [7] - Gold prices also saw a slight drop, with COMEX gold futures falling by over 1% [7] Geopolitical Developments - The third round of indirect negotiations between Iran and the U.S. began in Geneva, focusing on nuclear issues. Iran expressed readiness to engage in discussions regarding sanctions and nuclear rights [9][10] - The outcome of these negotiations could significantly impact regional tensions, with potential for either a temporary agreement or a shift towards military options if core disagreements persist [10]

Zai Lab (NasdaqGM:ZLAB) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsChristine Chiou - SVP of Investor RelationsHaichong Lin - AssociateJonathan Chang - Senior Managing Director of Emerging OncologyJosh Smiley - President and COOLi Watsek - DirectorMichael Yee - Global Head of Biotechnology ResearchRafael Amado - President and Head of Global Research and DevelopmentSamantha Du - Founder, Chairperson, and CEOYajing Qian - CFOConference Call ParticipantsAnupam Rama - Managing Direct ...

Financial Data and Key Metrics Changes - Fourth quarter total revenue increased by 17% year-over-year to $127.6 million, driven by strong contributions from XACDURO and NUZYRA [20] - Full year revenues grew by 15% to $460.2 million, reflecting steady progress across the commercial portfolio [20] - Loss from operations improved by 19% for the full year to $229.4 million, with a 25% improvement when adjusted for non-cash expenses [21] Business Line Data and Key Metrics Changes - The China business provided stability, with full year revenue growth of 15% year-over-year [6] - XACDURO performance reflected strong patient demand and expanding hospital adoption, although supply constraints limited full realization of demand [20] - VYVGART showed strong physician confidence and stable patient demand, with expectations for continued growth in 2026 [17] Market Data and Key Metrics Changes - The global oncology market presents a significant opportunity, with an estimated total addressable market exceeding $9 billion for Zoci in small cell lung cancer and neuroendocrine carcinomas [11] - The U.S. market for small cell lung cancer has approximately 15,000 patients available for second-line treatment and 25,000 for first-line treatment [61] Company Strategy and Development Direction - The company aims to build a globally competitive pipeline, focusing on execution and preparation for multiple growth opportunities in 2026 [5][19] - Business development remains a key lever, with targeted collaborations to explore novel combination strategies in oncology [17] - The company is leveraging its presence in China to access a fast-evolving innovation ecosystem, enhancing its global and regional pipeline [8] Management's Comments on Operating Environment and Future Outlook - Management highlighted a challenging macro and operating environment but expressed confidence in the stability provided by the China business [6] - The focus for 2026 is on maintaining the strength of the existing business while preparing for multiple growth opportunities, including the launch of KarXT and advancing late-stage assets [19] - Management emphasized the importance of disciplined spending and maintaining a strong cash position to support future growth [21] Other Important Information - The company has a strong cash position, ending the quarter with $790 million, which positions it well for executing its priorities [21] - The company is focused on expanding its global pipeline while preserving financial flexibility for future investments [46] Q&A Session Summary Question: Can you provide any color on how we should be thinking about revenues and expenses for 2026? - Management expects good growth opportunities for VYVGART and ZEJULA, with modest investments required to support launches [24] Question: Can you remind us of the implications of the intracranial activity in patients with brain mets for Zoci? - Zoci has shown an 80% response rate in patients with untreated brain metastases, which is a significant advantage [29] Question: Can you elaborate on the U.S., China development model? - The company is applying its efficient development structure in China to global trials, allowing for faster and higher quality execution [34] Question: What should we expect from KarXT in 2026 and 2027? - The commercial launch of KarXT is expected in the second quarter of 2026, with a focus on building disease awareness and establishing clinical confidence [73] Question: What is the expectation for completion of enrollment for Zoci? - Enrollment is expected to be completed by the end of the first quarter of next year, with a goal for accelerated approval in 2028 [48]

Financial Data and Key Metrics Changes - In Q4 2025, total revenue increased by 17% year-over-year to $127.6 million, with full-year revenues growing by 15% to $460.2 million [20][21] - Loss from operations improved by 19% for the full year to $229.4 million, and improved by 25% when adjusted for non-cash expenses [21] - The company ended the quarter with a strong cash position of $790 million [21] Business Line Data and Key Metrics Changes - The China business provided stability, with full-year revenue growth of 15% year-over-year [6] - XACDURO and NUZYRA contributed significantly to revenue growth, with XACDURO showing strong patient demand despite supply constraints [20] - VYVGART's revenue was stable, but Q4 reflected channel dynamics related to NRDL renewal and hospital purchasing patterns [17] Market Data and Key Metrics Changes - The company anticipates good growth opportunities for VYVGART and ZEJULA in 2026, despite facing a generic market for Lynparza [24] - The total addressable market for Zoci in small cell lung cancer and neuroendocrine carcinomas is estimated to exceed $9 billion [11] Company Strategy and Development Direction - The company is focused on execution and preparation for 2026, with several pipeline catalysts expected [6] - Business development remains a key lever, with targeted collaborations to explore novel combination strategies in oncology [17] - The company aims to build a lasting difference for patients while creating substantial value for shareholders [7] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of maintaining commercial profitability and preparing for multiple growth opportunities in 2026 [19] - The company is focused on strengthening its regional business and executing across its global pipeline [21] - Management expressed confidence in achieving corporate profitability, driven by top-line growth and disciplined investment [45] Other Important Information - The company has advanced Zoci from IND to global phase 3 in less than two years, reflecting the strength of its integrated U.S. and China development model [5] - The company is preparing for the commercial launch of KarXT in the second quarter of 2026, with a focus on building disease awareness and clinical confidence [19] Q&A Session Summary Question: Can you provide any color on how we should be thinking about revenues and expenses for 2026? - Management expects good growth opportunities for VYVGART and ZEJULA, with modest investments required to support launches [24][25] Question: Can you remind us of the implications of the intracranial activity in patients with brain mets for Zoci? - Zoci has shown an 80% response rate in patients with untreated brain metastases, which is a significant advantage [28] Question: Can you elaborate on the U.S., China development model? - The model allows for speedy development in China, which has led to successful registrations and efficient global trial participation [34][35] Question: What is the expectation for completion of enrollment and timing for Zoci's primary endpoint? - Enrollment is expected to finish by the end of Q1 2027, with a goal for accelerated approval in 2028 [50] Question: What is the strategy to grow VYVGART? - The focus is on increasing cycles per patient to a minimum of three, leveraging updated national guidelines [53][55]

Core Insights - The company reported a total revenue of $127.6 million for Q4 2025, representing a 17% year-over-year increase, and an annual total revenue of $460.2 million, up 15% year-over-year [1] - The net loss for Q4 2025 was approximately $50.4 million, narrowing by 38.29% year-over-year, while the annual net loss was about $175.5 million, a reduction of 31.73% year-over-year [1] - As of December 31, 2025, the company had cash and cash equivalents, short-term investments, and restricted cash totaling $789.6 million [1] Revenue and R&D Expenditure - Q4 2025 product revenue net was $127.1 million, a 17% increase from $108.5 million in Q4 2024, and the annual product revenue net was $457.2 million, up 15% from $397.6 million in 2024 [1] - R&D expenditure for Q4 2025 was $61.6 million, compared to $52.3 million in Q4 2024, while the total R&D expenditure for 2025 was $220.9 million, down from $234.5 million in 2024 [1] Strategic Developments - The reduction in net loss was attributed to product revenue growth outpacing operating expenses and a shift from foreign exchange losses to gains, although offset by decreased interest income [2] - The company plans to commercialize KarXT in the first half of 2026 and is actively developing targeted commercialization strategies and preparing for potential inclusion in the NRDL by 2027 [2] - Key data readouts for Povetacicept and elegrobart are expected in 2026, which may drive regional revenue growth [2] Leadership Insights - The CEO highlighted significant progress in the global innovation pipeline and steady advancement in commercialization efforts, emphasizing the importance of executing around key catalysts in 2026 [2] - The COO noted that KarXT is a crucial growth engine for the company, gaining recognition for its innovative mechanism and potential impact on schizophrenia patients, while also preparing for the approval of TIVDAK [2]

Core Insights - The company reported a total revenue of $127.6 million for Q4 2025, representing a 17% year-over-year increase, and an annual total revenue of $460.2 million, up 15% year-over-year [1] - The net loss for Q4 2025 was approximately $50.4 million, narrowing by 38.29% year-over-year, while the annual net loss was about $175.5 million, a reduction of 31.73% year-over-year [1] - As of December 31, 2025, the company had total cash, cash equivalents, short-term investments, and restricted cash amounting to $789.6 million [1] Revenue and R&D Expenditure - Q4 2025 product revenue netted $127.1 million, a 17% increase from $108.5 million in Q4 2024, and the annual product revenue netted $457.2 million, up 15% from $397.6 million in 2024 [1] - The R&D expenditure for Q4 2025 was $61.6 million, compared to $52.3 million in Q4 2024, while the annual R&D expenditure was $220.9 million, down from $234.5 million in 2024 [1] Strategic Developments - The reduction in net loss was attributed to product revenue growth outpacing operating expenses and a shift from foreign exchange losses to gains, although offset by decreased interest income [2] - The company plans to commercialize KarXT in the first half of 2026 and is actively developing targeted commercialization strategies and real-world evidence generation [2] - The CEO highlighted significant progress in the global innovation pipeline and emphasized the importance of executing around key catalysts in 2026 to prepare for future commercial growth [2]

Core Insights - The company reported total revenue of $127.6 million for Q4 2025 and $460.2 million for the entire year of 2025 [1] - Product revenue for Q4 2025 was $127.1 million, up 17% from $108.5 million in Q4 2024, with a constant exchange rate (CER) growth of 16% [1] - For the full year 2025, product revenue was $457.2 million, a 15% increase from $397.6 million in 2024, with a CER growth of 16% [1] - The growth in product revenue was primarily driven by increased sales of Dingyoule and Niuzainuo [1] Financial Performance - The net loss for Q4 2025 was $50.4 million, compared to a net loss of $81.7 million in Q4 2024 [1] - The total net loss for the year 2025 was $175.5 million, down from a net loss of $257.1 million in 2024 [1] - The reduction in net loss was mainly due to faster growth in product revenue compared to operating expenses and a shift from foreign exchange losses to gains, although offset by a decrease in interest income [1]

Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates NASDAQ:ZLAB | HKEX:9688 © 2026. Zai Lab. All Rights Reserved. This presentation contains forward-looking statements, including statements relating to our strategy and plans; potential of and expectations for our business, commercial products, and pipeline programs; our goals, objectives, and priorities and our expectations under our growth strategy (including our expectations regarding our commercial products and launches, and ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不會對因本公告全部或任何部分內 容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Zai Lab Limited 再鼎醫藥有限公司* (於開曼群島註冊成立的有限公司) （股份代號：9688） 截至2025年12月31日止年度的財務業績以及近期公司進展 再鼎醫藥有限公司（「本公司」）欣然公佈根據美國證券交易委員會的適用規則刊 發的本公司及其附屬公司截至2025年12月31日止年度的經審計合併財務業績 （「2025財年財務業績」）以及近期產品亮點和公司進展以及2025年預期重要里程 碑事件。 2025財年財務業績乃根據美國公認會計準則（「美國公認會計準則」）編製，而美 國公認會計準則有別於國際財務報告準則（「國際財務報告準則」）。 本公司預期於2026年3月31日或之前根據香港聯合交易所有限公司證券上市規則 （「上市規則」）刊發截至2025年12月31日止年度的全年業績，其中將載有聲明， 顯示根據美國公認會計準則及國際財務報告準則報告的財務報表之間的任何重大差 異的財務影響。 承董事會 ...

Revenue and Growth - In 2025, the company reported a 15% increase in total revenue to $460.2 million, with a 32% decrease in net loss to $175.5 million compared to the previous year[452]. - Product revenue increased by $59.6 million, primarily driven by strong demand for XACDURO and increased market penetration for NUZYRA[469]. - The company expects continued revenue growth in 2026, driven by existing commercial products and new product launches[453]. - Collaboration revenue increased by 116% to $2.974 million in 2025, reflecting promotional activities in mainland China[466]. - ZEJULA remained the leading PARP inhibitor in hospital sales for ovarian cancer in mainland China despite competitive dynamics[452]. Expenses and Financial Performance - The cost of product revenue rose by $43.4 million in 2025, mainly due to increased sales volumes and higher inventory provisions for VYVGART Hytrulo[470]. - Research and development expenses decreased by $13.6 million in 2025, totaling $220.9 million, primarily due to a $18.3 million reduction in personnel compensation[472][473]. - Clinical program expenses increased by $0.8 million to $86.9 million, while pre-clinical program expenses decreased by $7.6 million to $24.3 million[474]. - Selling, general, and administrative expenses decreased by $21.1 million in 2025, totaling $277.6 million, mainly due to resource prioritization efforts[476]. - Net loss for 2025 was $175.5 million, a reduction from a net loss of $257.1 million in 2024, resulting in a loss per ordinary share of $0.16[482]. Cash Flow and Investments - Net cash used in operating activities decreased by $64.1 million in 2025, totaling $150.8 million, primarily due to a reduction in net loss[502]. - Net cash provided by investing activities was $307.9 million in 2025, a significant shift from net cash used of $375.2 million in 2024[503]. - As of December 31, 2025, the company had cash and cash equivalents of $789.6 million, expected to meet cash requirements for at least the next 12 months[498]. - As of December 31, 2025, the company had cash and cash equivalents of $679.6 million, an increase from $449.7 million in 2024[514]. - Short-term investments decreased from $330.0 million in 2024 to $10.0 million in 2025[514]. Debt and Financial Obligations - The company had short-term debt outstanding of $204.5 million as of December 31, 2025, under debt arrangements with Chinese financial institutions[497]. - Short-term debt increased from $131.7 million in 2024 to $204.5 million in 2025[519]. - As of December 31, 2025, the company may be required to pay up to $170 million in development and regulatory milestone payments for current clinical programs[463]. Risk Management and Currency Exposure - The company manages credit risk through ongoing monitoring and limiting credit based on payment history[515]. - The investment portfolio primarily consists of time deposits aimed at preserving principal and maximizing income[518]. - The company is exposed to foreign exchange risks related to the conversion of RMB into U.S. dollars and HK dollars[511]. - The HK dollar is pegged to the U.S. dollar at approximately HK$7.80 to US$1.00, but future changes are uncertain[512]. - A hypothetical 10% relative change in interest rates would not materially impact future interest income[518]. - Interest income decreased by $4.1 million in 2025, attributed to reduced cash and cash equivalents[477]. - Foreign currency gains were $19.6 million in 2025, compared to losses of $15.1 million in 2024, driven by RMB appreciation against the U.S. dollar[479]. Strategic Initiatives - The company has multiple late-stage product candidates and ongoing pivotal trials, indicating a strong pipeline for future growth[449]. - In 2025, the company appointed Dr. Shan He as Senior Vice President, Chief Business Officer, to enhance its business development strategy[455]. - The company anticipates significant investments in research and development to support its pipeline and long-term competitiveness[460].